JOP20210113A1 - مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم - Google Patents

مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم

Info

Publication number
JOP20210113A1
JOP20210113A1 JOP/2021/0113A JOP20210113A JOP20210113A1 JO P20210113 A1 JOP20210113 A1 JO P20210113A1 JO P20210113 A JOP20210113 A JO P20210113A JO P20210113 A1 JOP20210113 A1 JO P20210113A1
Authority
JO
Jordan
Prior art keywords
antagonists
alpha
treatment
sleep apnea
adrenoceptor subtype
Prior art date
Application number
JOP/2021/0113A
Other languages
English (en)
Inventor
Hahn Michael
Delbeck Martina
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of JOP20210113A1 publication Critical patent/JOP20210113A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بمناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي)، على وجه الخصوص مركبات بيبريدينيل -بيريميدينيل -رباعي هيدروكينولين ومركبات بيبريدينيل -بيريدينيل -رباعي هيدروكينولين تحمل بدائل بالصيغة (I) لاستخدامها في طريقة لمعالجة و/أو الوقاية من اضطرابات التنفس المرتبطة بالنوم، ويفضل انقطاع النفس الانسدادي والمركزي أثناء النوم والشخير.
JOP/2021/0113A 2018-11-20 2019-11-13 مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم JOP20210113A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18207138 2018-11-20
PCT/EP2019/081133 WO2020104266A1 (en) 2018-11-20 2019-11-13 α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS FOR THE TREATMENT OF SLEEP APNEA

Publications (1)

Publication Number Publication Date
JOP20210113A1 true JOP20210113A1 (ar) 2023-01-30

Family

ID=64402019

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2021/0113A JOP20210113A1 (ar) 2018-11-20 2019-11-13 مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم

Country Status (16)

Country Link
US (1) US20220016113A1 (ar)
EP (1) EP3883933A1 (ar)
JP (1) JP2022507733A (ar)
KR (1) KR20210093949A (ar)
CN (1) CN113166166B (ar)
AU (1) AU2019382737A1 (ar)
BR (1) BR112021007830A2 (ar)
CA (1) CA3120152A1 (ar)
CL (1) CL2021001315A1 (ar)
EA (1) EA202191375A1 (ar)
IL (1) IL283183A (ar)
JO (1) JOP20210113A1 (ar)
MA (1) MA55129A (ar)
MX (1) MX2021005842A (ar)
UA (1) UA127906C2 (ar)
WO (1) WO2020104266A1 (ar)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2850377B1 (fr) * 2003-01-23 2009-02-20 Sanofi Synthelabo Derives d'arylalkylcarbamates, leur preparation et leur application en therapeutique
EP2691384B1 (en) * 2011-03-28 2016-10-26 MEI Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CN105980374A (zh) 2013-12-19 2016-09-28 拜耳制药股份公司 取代的哌啶基四氢喹啉
JOP20200052A1 (ar) * 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
CA2934132A1 (en) * 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
US20180235934A1 (en) 2015-08-18 2018-08-23 Massachusetts Institute Of Technology Noradrenergic drug treatment of obstructive sleep apnea
BR112018011783A2 (pt) * 2015-12-10 2018-12-04 Bayer Pharma Aktiengesellschaft derivados de 2-fenil-3-(piperazinometil)imidazo[1,2-a]piridina, como bloqueadores dos canais de task-1 e task-2 para o tratamento de transtornos respiratórios relacionados ao sono

Also Published As

Publication number Publication date
CA3120152A1 (en) 2020-05-28
CL2021001315A1 (es) 2021-10-22
EP3883933A1 (en) 2021-09-29
CN113166166B (zh) 2024-09-10
AU2019382737A1 (en) 2021-05-20
JP2022507733A (ja) 2022-01-18
WO2020104266A1 (en) 2020-05-28
BR112021007830A2 (pt) 2021-08-03
KR20210093949A (ko) 2021-07-28
EA202191375A1 (ru) 2021-09-21
UA127906C2 (uk) 2024-02-07
IL283183A (en) 2021-06-30
MX2021005842A (es) 2021-07-15
MA55129A (fr) 2022-02-23
US20220016113A1 (en) 2022-01-20
CN113166166A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
GEP20227366B (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
JOP20210059A1 (ar) مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم
PH12018501235A1 (en) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
PH12019500131A1 (en) Substituted diazahetero-bicyclic compounds and their use
MX2022010349A (es) Metodos y composiciones para el tratamiento de apnea del sue?o.
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
SA521422114B1 (ar) عملية لإنتاج أشكال جرعة صيدلانية تحتوي على مثبطات قناة واستخدامها في علاج اضطراب التنفس task-1 و task-3،
MX2023000369A (es) Combinación de antagonistas del receptor adrenérgico a2 subtipo c (alfa 2c) con un bloqueador de canales task1/3 para el tratamiento de la apnea del sueño.
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
JOP20210113A1 (ar) مناهضات لمستقبلات ألفا 2 الأدرينالية من النمط الثانوي سي (ألفا-2سي) لمعالجة انقطاع النفس أثناء النوم
MX2024007768A (es) Combinacion de un antagonista de adrenoreceptor a2 subtipo c (alfa-2c) con un inhibidor de recaptacion de norepinefrina para el tratamiento de apnea del sue?o.
MX2024007767A (es) Combinacion de un antagonista del adrenoceptor a2 subtipo c (alfa-2c) con un antagonista del receptor muscarinico para el tratamiento de la apnea del sue?o.
MX2024008522A (es) Derivados de 2,3-dihidrobenzo[b][1,4]dioxin-2-ilmetil)piperazin-1- ilo para el tratamiento de la apnea del sue?o.
MX2024008523A (es) Antagonistas del adrenoceptor a2 subtipo c para el tratamiento de la apnea del sue?o.
EA201991540A1 (ru) Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3 и их применение для лечения нарушений дыхания
EA201991538A1 (ru) Фармацевтические лекарственные формы, содержащие ингибиторы каналов task-1 и task-3, и их применение для лечения нарушений дыхания
MX2024007764A (es) Combinacion de un bloqueante de canales task1/3 con un inhibidor de la recaptacion de norepinefrina para el tratamiento de la apnea del sue?o.
EA201990341A1 (ru) Замещенные диазагетеробициклические соединения и их применение